Prof Richard Upton began his research career in 1981 as a technician for Prof Laurie Mather and Prof Bill Runciman at Flinders Medical Centre, who at that time were beginning to use a chronically instrumented sheep preparation to examine the influence of general anaesthesia on drug disposition. It was clear that this experimental preparation was unique both nationally and internationally, and could allow unprecedented insight into the physiological basis of the disposition of drugs used in anaesthesia and intensive care.
Through various higher degrees and post-doctoral work, Dr Upton sought to develop and exploit this experimental preparation at FMC, and from 1989 at the Royal Adelaide Hospital. At the RAH this required supervising and... Read more
About me
Prof Richard Upton began his research career in 1981 as a technician for Prof Laurie Mather and Prof Bill Runciman at Flinders Medical Centre, who at that time were beginning to use a chronically instrumented sheep preparation to examine the influence of general anaesthesia on drug disposition. It was clear that this experimental preparation was unique both nationally and internationally, and could allow unprecedented insight into the physiological basis of the disposition of drugs used in anaesthesia and intensive care.
Through various higher degrees and post-doctoral work, Dr Upton sought to develop and exploit this experimental preparation at FMC, and from 1989 at the Royal Adelaide Hospital. At the RAH this required supervising and setting up new large animal and analytical laboratories. In 1992 he moved from being a National Health and Medical Research Council Fellow to a Medical Scientist at the RAH. From 1990 to 2003 his laboratory had continuous funding (approximately 2 million dollars) from the National Heart Foundation or NHMRC, and produced over 85 publications. These laboratory facilities were exploited to investigate the basic physiological mechanisms underlying the absorption, distribution, metabolism and elimination (ADME) of a number of drugs used in anaesthesia.
Also in this period, Dr Upton developed a number of physiological pharmacokinetic-pharmacodynamic computer models that added a crucial dimension to the analysis of the data from this laboratory. From 2003 industry funding was used to maintain Dr Upton's laboratory. This culminated in a significant contribution to the preclinical development of a new intravenous sedative, including modelling and scaling of animal data to predict first dose in man.
Clinical work included conducting Phase I and other clinical trials, and particularly the pharmacokinetic analysis of data from clinical trials using NONMEM and other software for mid-sized European drug companies and their collaborators. From November 2008, Dr Upton has worked as a pharmacometric consultant for Projections Research Incorporated, USA, consulting to major pharmaceutical companies.
In March 2010 he joined the University of South Australia as Professor of Pharmacometrics (part-time) and balances academic and consulting work.
Prof Upton has published over 130 papers and has benefited from being a successful basic researcher, from seeing the needs of industry for clinical and preclinical studies and from being a close collaborator of clinicians. This wide perspective has led him to advocate for innovative ways of translating new knowledge into effective drug development and drug treatments for patients. He is of the conviction that a modelling and simulation approach is an important step forward in maximising the efficiency of drug development, and for bridging the knowledge-practice gap in patient care.
In 2001, the President and President-elect of the International Society for Anaesthetic Pharmacology published an overview of their discipline, and described Dr Upton's work as being at the forefront of current thinking. In 2008, a "State of the Art" review on "Contributions of PK/PD Modeling to Intravenous Anesthesia" in Clinical Pharmacology and Therapeutics quoted 4 papers by Dr Upton and his co-workers. He is a former Editor of the British Journal of Pharmacology (Impact factor 3.8). He has been an invited speaker at national meetings, and in the UK, New Zealand, Spain and Denmark.
About me
About me
Doctor of Philosophy Flinders University
Bachelor of Sciences Flinders University
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2021 |
|
2019 |
1
|
2008 |
|
Year | Output |
---|---|
2024 |
Open access
6
6
3
|
2024 |
3
3
|
2024 |
Open access
|
2024 |
Open access
|
2024 |
Open access
|
2023 |
Open access
8
9
38
|
2023 |
Open access
4
4
1
|
2022 |
Open access
13
12
6
|
2022 |
Open access
18
15
6
|
2022 |
Open access
4
3
1
|
2021 |
Open access
35
28
4
|
2021 |
2
2
|
2021 |
Open access
2
2
|
2020 |
7
6
|
2020 |
Open access
14
12
1
|
2020 |
Open access
5
4
1
|
2020 |
Open access
2
2
2
|
2020 |
25
21
|
2019 |
Open access
11
9
1
|
2019 |
Open access
9
8
4
|
2019 |
7
7
4
|
2019 |
Open access
8
8
|
2018 |
Open access
5
5
|
2018 |
6
7
1
|
2018 |
Open access
15
13
1
|
2018 |
17
15
|
2017 |
231
191
11
|
2017 |
Open access
9
9
3
|
2017 |
Open access
8
7
10
|
2017 |
Open access
4
5
|
2017 |
29
29
3
|
2016 |
86
92
6
|
2016 |
66
30
1
|
2016 |
28
24
14
|
2016 |
8
14
|
2016 |
Open access
27
27
15
|
2016 |
65
63
|
2016 |
6
4
7
|
2016 |
Open access
35
27
1
|
2016 |
Open access
|
2015 |
Open access
6
5
|
2015 |
Open access
81
71
12
|
2015 |
Open access
6
5
|
2015 |
Open access
16
12
|
2015 |
Open access
55
26
|
2014 |
Open access
8
8
|
2014 |
6
5
1
|
2014 |
7
7
|
2014 |
Open access
4
4
|
2014 |
Open access
21
36
|
2014 |
Open access
7
7
|
2014 |
Open access
15
15
1
|
2014 |
16
17
|
2014 |
Open access
201
146
|
2014 |
Open access
6
5
|
2013 |
Open access
581
374
|
2012 |
29
27
|
2012 |
9
6
|
2012 |
Open access
370
246
|
2012 |
Open access
11
10
|
2011 |
Open access
38
31
|
2011 |
35
24
|
2010 |
24
22
|
2010 |
102
84
|
2010 |
30
25
|
2010 |
Open access
40
39
|
2010 |
22
20
|
2009 |
|
2009 |
Open access
14
13
|
2009 |
Open access
45
40
|
2008 |
56
48
|
2008 |
24
25
|
2008 |
91
79
|
2008 |
119
100
|
2008 |
72
|
2008 |
10
10
|
2008 |
Open access
38
35
|
Research
External engagement & recognition
Organisation | Country |
---|---|
Aalborg University | DENMARK |
Aarhus University | DENMARK |
Aarhus University Hospital | DENMARK |
Academic Medical Centre | NETHERLANDS |
AstraZeneca R&D Lund | SWEDEN |
Austin Health | AUSTRALIA |
Copenhagen Business School | DENMARK |
Copenhagen University | DENMARK |
Copenhagen University Hospital | DENMARK |
Daping Hospital | CHINA |
Environment Protection Authority Victoria | AUSTRALIA |
Federal Institute for Risk Assessment | GERMANY |
Flinders University | AUSTRALIA |
Ghent University | BELGIUM |
Icahn School of Medicine at Mount Sinai | UNITED STATES |
Mayne Pharma Pty Ltd | AUSTRALIA |
Monash University | AUSTRALIA |
Mount Sinai Hospital | UNITED STATES |
National Defense Medical College | JAPAN |
Norwegian University of Science and Technology | NORWAY |
Nycomed Pharma | DENMARK |
Ohio State University | UNITED STATES |
Pfizer (United States) | UNITED STATES |
Pfizer Australia Pty Ltd | AUSTRALIA |
Pfizer Corporation | UNITED STATES |
Postgraduate Institute of Medical Education and Research | INDIA |
Private Individual | UNITED KINGDOM |
Projections Research Inc. | UNITED STATES |
Royal Adelaide Hospital | AUSTRALIA |
Royal Melbourne Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
Senversa Pty Ltd | AUSTRALIA |
St George Hospital | INDIA |
Stanford University | UNITED STATES |
Stellenbosch University | SOUTH AFRICA |
Taylor's University | MALAYSIA |
The Danish University of Pharmaceutical Sciences | DENMARK |
The Royal Marsden NHS Foundation Trust | UNITED KINGDOM |
University Children's Hospital Basel | SWITZERLAND |
University of Adelaide | AUSTRALIA |
University of Copenhagen | DENMARK |
University of Oxford | UNITED KINGDOM |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
Women's and Children's Hospital | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
MemberAustralasian Pharmaceutical Science Association (APSA) |
2018 |
MemberPopulation Analysis Group of Australia and New Zealand |
2018 |
MemberAmerican Society of Pharmacometrics |
2018 |
MemberPopulation Analysis Group of Australia and New Zealand |
2017 |
MemberAustralasian Pharmaceutical Science Association (APSA) |
2017 |
MemberAmerican Society of Pharmacometrics |
2017 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
A computational approach to improve the prediction of fraction unbound to enhance pharmacokinetic (PK) and biopharmaceutic models | Current |
Population variability of the omega-3 index and its relevance to chronic inflammatory disease states | Current |
Development of patient-centric conventional and 3D printed buccal films: enabling personalised medicine | Completed |
Individualisation of leflunomide dosing in rheumatoid arthritis patients | Completed |
Investigating pharmacometric approaches to individualised medicine in autoimmune diseases | Completed |
Investigation of the toxicokinetics of per- and polyfluoroalkyl substances (PFAS) in cattle and application to risk assessment | Completed |
Pharmacometric methodologies and their use for lenalidomide drug development in chronic lymphocytic leukaemia | Completed |
Population-based models of the effect of food and pH on oral drug absorption | Completed |